152 results about "Exovesicles" patented technology

The invention provides a method for separating extracellular vesicles from a milk source, which comprises the step of adding a dispersing agent before adding a precipitator into the milk source to precipitate casein so as to reduce the wrapping of protein precipitation on the extracellular vesicles and improve the yield of the extracellular vesicles, thereby obtaining a milk source extract rich in the extracellular vesicles.

The invention provides a rapid quantitative analysis method for an outer vesicle proteome, and belongs to the technical field of quantitative analysis of the outer vesicle proteome. According to the rapid quantitative analysis method for the outer vesicle proteome, firstly, a high-quality outer vesicle sample is obtained through low-speed centrifugation, ultra-speed centrifugation and membrane filtration; and obtaining proteome data by utilizing two-dimensional electrophoresis and mass spectrometry. Then, a mathematical model equation set is constructed for preliminary analysis, a protein interaction network is optimized through an embedded game optimization index model, and feature extraction and quantitative analysis are conducted through a convolution parameter adaptive function and a residual network deep learning model; finally, a quantitative analysis result containing the protein expression level and the function importance is generated in combination with the multi-dimensional protein expression contribution index, and the technical problem that in the prior art, in the rapid quantitative analysis process of the outer vesicle proteome, the protein component complexity is high, and consequently the quantitative precision is low is solved.

The invention discloses a preparation method of artemisia apiacea extracellular vesicles, which comprises the following steps: step 1, pre-treating artemisia apiacea, carrying out primary centrifugal treatment, removing large plant tissues and cell debris, carrying out secondary centrifugal treatment, filtering by a needle filter, and collecting; step 2, transferring the filtered suspension to a sucrose density gradient solution, then carrying out third centrifugal treatment, collecting the solution with the concentration of 30% in the layer, and carrying out fourth centrifugal treatment to obtain artemisia apiacea extracellular vesicles; the invention further discloses an artemisia apiacea extracellular vesicle, a pharmaceutical composition for treating cerebral apoplexy, a medicine and application of the artemisia apiacea extracellular vesicle in preparation of the medicine for treating cerebral apoplexy. The naturally-sourced vesicle delivery system provided by the invention is expected to have higher safety and lower toxic and side effects, and the enrichment concentration of the therapeutic component at the focus part of cerebral apoplexy is improved, so that the bioavailability and the treatment efficiency of the medicine are remarkably improved.

The invention discloses a kit for detecting miRNAs of multiple extracellular vesicles based on a TtAgo-driven rolling circle amplification technology and application of the kit, a platform combines TtAgo protein and RCA reaction, cooperates with endonuclease activity and DNA polymerase activity of TtAgo, accurately controls reaction kinetic balance between temperature and enzyme activity, not only does not damage the cutting activity of TtAgo, but also can detect miRNAs of multiple extracellular vesicles. The method provided by the invention can be used for detecting multiple extracellular vesicles miRNAs, ensures strong polymerization amplification performance, creates a strong one-step single-tube experiment, greatly simplifies the experimental process, shortens the detection time, realizes ultra-sensitive and specific detection of nucleic acid markers, and can be used for detecting multiple extracellular vesicles miRNAs.

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing and treating or improving heart diseases. The plant exovesicle provided by the invention has the advantages of low toxicity, high biocompatibility, biodegradability, no induction of immunogenicity, high yield and large-scale preparation. A large number of experimental studies prove that the pseudo-ginseng external vesicles disclosed by the invention have a remarkable heart disease prevention and treatment effect. Therefore, development and application of the fresh pseudo-ginseng medicine are promoted.

The current invention relates to isolated Extracellular Vesicles (EVs) wherein said EVs comprise the miRNA markers hsa-miR-125b-5p, hsa-miR-199a-3p, hsa-miR-199b-3p and hsa-miR-16-5p.

The present invention provides a method of recovering an extracellular vesicle from an extracellular vesicle-containing sample. More specifically, the present invention provides a method of recovering the extracellular vesicle that includes separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

The invention discloses an application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.

The present invention provides extracellular vesicle compositions. Also provided are methods of making an extracellular vesicle loaded scaffold using the extracellular vesicle compositions to increase revascularization. Methods of using the extracellular vesicle compositions and the extracellular vesicle loaded scaffold are provided. The scaffold may increase blood flow and oxygenation of the tissue thereby aiding in treatment of disease and injury.

Several embodiments disclosed herein relate to methods and compositions for treatment of inflammation. In several embodiments, therapeutic nucleic acids enriched in extracellular vesicles from fibroblasts engineered to overexpress TDO2 are provided. In several embodiments, a therapeutically effective amount of the isolated nucleic acid is administered to treat an inflammatory condition. In several embodiments, the inflammation is secondary to tissue damage or an infection.

The invention belongs to the technical field of traditional Chinese medicines, and discloses an immature bitter orange-derived extracellular vesicle-like nanoparticle, which is characterized in that the immature bitter orange-derived extracellular vesicle-like nanoparticle is prepared by the steps of crushing immature bitter orange, filtering, centrifuging and resuspending, the average particle size is 60-120 nm, and the particle size of the immature bitter orange-derived extracellular vesicle-like nanoparticle is 20-30 nm. The extracellular vesicle-like nanoparticles are used for entrapment of at least one of naringin, neohesperidin, naringenin and hesperidin. The extracellular vesicle-like nanoparticles derived from immature bitter oranges are simple in preparation method, have liver targeting and good stability, and can be used for preparing medicines for preventing and / or treating liver injury, depression and breast cancer.

Disclosed in the present invention is a use of royal jelly extracellular vesicles (RJEVs) in the preparation of a pharmaceutical composition for treating wounds in individuals suffering from diabetes, wherein the pharmaceutical composition comprises at least one carrier, and the at least one carrier has the characteristics of adhering to the skin of the individuals.

Provided herein are recombinant tumor-selective viral particles comprising a nucleic acid encoding a recombinant polypeptide for directing extracellular vesicles (EVs) to at least one target cell, the recombinant polypeptide comprising at least one targeting moiety for directing the EVs to the at least one target molecule expressed by the at least one target cell; at least one EV anchor polypeptide; and at least one intravesicular polypeptide. The viral particle may be derived from an oncolytic virus. Recombinant polypeptides for programming EVs to target specific molecules are also provided. Therapeutic EVs for delivering payload polypeptides (and / or cargo molecules) to target cells, e.g., in vaccine or cell-free "CAR-T"-like applications, are also described, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE-like applications. Furthermore, oncolytic viruses may be modified to provide additional therapeutic benefits by infecting tumor cells and administering the programmed EVs.

The invention relates to the technical field of biological medicines, in particular to application of extracellular vesicles of Ackermann muciniphila in preparation of trichina control products. Experiments prove that by supplementing the AKK bacterium extracellular vesicles, the intestinal flora of a mouse can be remarkably improved, the immune balance of a host is regulated, and the pathological change of the intestinal tract of the mouse can be improved. Experimental results show that the AKK bacterium extracellular vesicles have a certain protection effect on trichina infected mice and have the advantages of being efficient, safe, easy to produce on a large scale and the like, and a brand new technical solution is provided for prevention and treatment of trichinosis.

Described are method of producing extracellular vesicles from cells by exposing the cells to near UV light. Compositions containing the extracellular vesicles and methods of using the extracellular vesicles are also described.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

Provided are a biological material for restoring ovarian functions, a preparation method therefor and the use thereof, relating to the technical field of biological materials. A large number of experiments verify that: it is found that a specific biological protein component for reversing ovarian functions in extracellular vesicles is the growth differentiation factor 9 (GDF-9), and the mechanism of action thereof for restoring the ovary is determined, and therefore extracellular vesicles (GOEs) that overexpress GDF-9 serve as an active substance, and by means of extraction and purification of said component, the purpose of targeted therapy is achieved.

The purpose of the present disclosure is to provide a pharmaceutical composition having excellent therapeutic effects in the treatment of central nervous system diseases.　This pharmaceutical composition for intravascular administration is used for treating central nervous system diseases and contains a purified extracellular vesicle product. The purified extracellular vesicle product is obtained by a method for producing a purified extracellular vesicle product, the method comprising: (i) a purification step for bringing a solution to be treated containing extracellular vesicles and foreign substances into contact with size-exclusion and anion-exchange carriers to obtain a treated solution containing the extracellular vesicles; and (ii) a membrane filtration step for subjecting the treated solution to membrane filtration to obtain a concentrated solution of the extracellular vesicles. The pharmaceutical composition has excellent therapeutic effects in the treatment of central nervous system diseases.

A composition comprising primed extracellular vesicles and a biologically or pharmaceutically acceptable carrier, wherein the primed extracellular vesicles comprise an upregulated miRNA, and a fold change of the upregulated miRNA of the primed extracellular vesicles compared to miRNA of naturally occurring extracellular vesicles is greater than 1. A method for preventing, treating, or ameliorating a bone defect or a dental defect comprising administering the composition to a subject in need thereof. A method for producing the composition, comprising: cultivating a stem cell in a culture medium containing a Polygonum multiflorum Thunb extract and at least one selected from the group consisting of baicalin and bone morphogenetic protein 6 to obtain a cell culture.

The invention relates to the technical field of biological medicine, in particular to a bacterial outer vesicle and a preparation method and application thereof, and the surface of the bacterial outer vesicle contains specific binding polypeptide TssS capable of expressing manganese ions. The bacterial ectovesicles can capture endogenous manganese ions, interfere with activation of an STING innate immune pathway, and are combined with an E3 ubiquitin ligase ligand VHL, so that activation of host anti-tumor immune response is realized.

Disclosed herein are methods for detecting biological entities or chemicals in a sample, wherein the biological entities or chemicals are associated with extracellular vesicles. The disclosed methods include the steps of: (a) processing the sample; (b) using a detection assay to detect the presence of extracellular vesicles and isolate the extracellular vesicles; (c) processing the extracellular vesicles to expose or release the biological entities or chemicals; and (e) detecting the biological entities or chemicals released from the extracellular vesicles. In certain embodiments, the extracellular vesicles are associated with proteins, glycoproteins, peptides, lipids, nucleic acids, or other cellular components. The detection methods are useful for identifying the presence of microbial antigens associated with Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, and Histoplasma species.

The invention relates to an extracellular vesicle-frozen gel scaffold as well as an integrated preparation method and application thereof, and belongs to the technical field of biotechnology and tissue engineering materials. The problems that in the prior art, extracellular vesicles are prone to being damaged by low temperature in the frozen gel preparation process, a traditional cryoprotectant is not compatible with a stent process, and burst release and action time is short in a vesicle physical adsorption method are solved. The method comprises the following steps: mixing extracellular vesicles with a trehalose solution, and standing to obtain a vesicle-trehalose mixed solution; mixing with the support material prepolymer solution, and adding a photoinitiator to form a composite precursor solution; freezing the solution, and performing cross-linking solidification to form a three-dimensional porous gel scaffold; and unfreezing and washing to obtain the stent. The trehalose is introduced as a cryoprotectant, vesicle activity protection and stent structure forming are synchronously achieved in low-temperature forming, and the prepared stent can achieve controllable slow release of vesicles and has good application prospects in the field of tissue repair and regeneration.

The invention relates to the technical field of protection of external vesicles, in particular to a preserving fluid for improving the stability of the external vesicles and a preparation method and application of the preserving fluid. The invention provides a preserving fluid for improving stability of external vesicles. The preserving fluid comprises an acidic buffer solution and a stabilizer, the acidic buffer solution is a citric acid buffer solution, and the stabilizer is cyclodextrin or a functionalized derivative thereof; and the pH value of the preservation solution is 6.0-7.0. The preserving fluid provided by the invention can stably store the external vesicles under the condition of low temperature (4 DEG C and-80 DEG C), and can effectively inhibit damage, such as membrane rupture and protein inactivation, of the external vesicles in the low-temperature storage process.

The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via a dual cleavable linker and an anchoring moiety. The extracellular vesicles can be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

The invention relates to the technical field of microorganisms, in particular to application of extracellular vesicles of lactic acid bacteria in preparation of drugs for treating or relieving inflammation. According to the application disclosed by the invention, after KLK29EVs and KEF14EVs are used for treating inflammation induced by LPS (Lipopolysaccharide), more dimers are limited in cytoplasm by inhibiting the phosphorylation degree of I kappa B alpha, and the transcriptional activity of NF-kappa B is directly inhibited by reducing the expression quantity of p65. Meanwhile, important downstream target genes iNOS and COX-2 of an NF-kappa B signal channel are inhibited, and related inflammations are effectively prevented. The discovery provides a new thought for developing an anti-inflammatory treatment strategy of the KLK29EVs and the KEF14EVs.

The invention discloses a bifidobacterium breve extracellular vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The extracellular vesicles are obtained by the following steps: carrying out anaerobic culture on Bifidobacterium breve FB-342 in a culture medium containing L-cysteine, and then carrying out differential centrifugation, filtration and ultracentrifugation on the cultured Bifidobacterium breve FB-342. According to the invention, the extracellular vesicles with definite physicochemical characteristics (the average particle size is about 143.1 nm and the purity is about 1.76 * 10 < 11 > parts / g protein) are successfully prepared from the bifidobacterium breve FB-342 for the first time, and experimental results show that the prepared extracellular vesicles of the bifidobacterium breve FB-342 have obvious potential for treating ulcerative colitis in cell and animal models, and can be used for preparing the extracellular vesicles of the bifidobacterium breve FB-342 for treating ulcerative colitis. And a new strategy based on the probiotic vesicles is provided for treatment of ulcerative colitis.

The invention discloses a preparation method of Brassica rapa L.-derived extracellular vesicle-like particles and an application of the Brassica rapa L.-derived extracellular vesicle-like particles in pulmonary fibrosis resistance. The preparation method comprises the following steps: raw material pretreatment and homogenate preparation: cleaning and grinding the common turnip, adding the common turnip into PBS (Phosphate Buffer Solution) which is 1.5 times of the mass of the medicinal material, soaking for 180 minutes, putting into a homogenizer to prepare homogenate, filtering, standing, and taking supernatant; performing super-gradient centrifugal purification: performing gradient centrifugation, taking supernatant and discarding precipitate; carrying out ultra-high-speed centrifugal collection, namely carrying out ultra-high-speed centrifugal collection on the supernatant at 120000g for 120 minutes and taking precipitate; and re-suspending and storing: re-rotating and precipitating by using PBS to obtain BREVLPs, and storing at ultralow temperature for later use. The extracellular vesicle-like particles (BREVLPs) are prepared from the common turnip for the first time, the preparation method is simple in process, convenient to operate, wide in source of the raw material common turnip, low in cost and suitable for large-scale production, and the problems that existing animal-derived extracellular vesicle-like particles are high in culture cost and complex in process are solved.

The present invention relates to extracellular vesicles having FGF21 linked to the surface thereof, and use thereof. The extracellular vesicles according to one embodiment can alleviate steatosis, reduce inflammation and fibrosis, and alleviate a decrease in bone density, which is a side effect occurring when FGF21 is used alone, and thus can be effectively used for preventing and treating liver diseases including metabolic abnormality-related steatohepatitis.